Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis

[PR Newswire] – LA JOLLA, Calif., Aug. 5, 2014 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered . . . → Read More: Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis Similar Articles: Biogen Idec Inc (NASDAQ:BIIB) | ISIS Pharmaceuticals’ and Biogen idec’s innovative collaboration voted breakthrough alliance of 2014 Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – UPDATE 2-Biogen profit rises as new multiple sclerosis drug shines